DB
ABCL icon

Dmitry Balyasny’s AbCellera Biologics ABCL Stock Holding History

Dmitry Balyasny’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-404,405
Closed -$2.03M – 3031
2025
Q3 		$2.03M Buy
404,405
+369,493
+1,058% +$1.63M ﹤0.01% 1782
2025
Q2 		$120K Sell
34,912
-46,171
-57% -$115K ﹤0.01% 2673
2025
Q1 		$181K Buy
81,083
+67,562
+500% +$194K ﹤0.01% 2607
2024
Q4 		$39.6K Buy
+13,521
New +$37.7K ﹤0.01% 2644
2024
Q3 		– Sell
-34,794
Closed -$103K – 2681
2024
Q2 		$103K Sell
34,794
-23,716
-41% -$89.7K ﹤0.01% 2401
2024
Q1 		$265K Buy
58,510
+43,657
+294% +$223K ﹤0.01% 2306
2023
Q4 		$84.8K Buy
+14,853
New +$68.8K ﹤0.01% 2391
2023
Q3 		– Sell
-1,134,269
Closed -$7.33M – 2199
2023
Q2 		$7.33M Buy
+1,134,269
New +$7.74M 0.02% 912
2023
Q1 		– Sell
-153,025
Closed -$1.55M – 2574
2022
Q4 		$1.55M Buy
153,025
+102,193
+201% +$1.18M ﹤0.01% 1510
2022
Q3 		$503K Buy
+50,832
New +$558K ﹤0.01% 2036
2022
Q2 		– Sell
-62,339
Closed -$608K – 2691
2022
Q1 		$608K Buy
+62,339
New +$590K ﹤0.01% 1771

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dmitry Balyasny's ABCL Position: Q4 2025 in Review

Dmitry Balyasny sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 404,405 shares — an estimated $2.03M sold.

Dmitry Balyasny first reported a position in ABCL in Q1 2022 and held it in 11 quarters. The position peaked at $7.33M in Q2 2023. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

  • Dmitry Balyasny reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 404,405 AbCellera Biologics shares in Q4 2025, an estimated $2.03M.
  • Dmitry Balyasny first reported a position in AbCellera Biologics in Q1 2022 and held it in 11 quarters.
  • Dmitry Balyasny's AbCellera Biologics position peaked at $7.33M in Q2 2023.
  • 144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.